NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Lenalidomide for the treatment of myelodysplastic syndromes associated with a deletion 5q cytogenic abnormality in people with red blood cell transfusion dependence

[redacted], [redacted]
Email: TACommC@nice.org.uk

Fax: [redacted]
Post: NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

I confirm that:

- I agree with the content of the statement submitted by MDS UK Patient Support Group and consequently I will not be submitting a personal statement.

Name: .....Professor Rodney Taylor.....

Signed: .....[redacted].....

Date: .....17/04/13.....